Class / Patent application number | Description | Number of patent applications / Date published |
424211100 | Paramyxoviridae (e.g., parainfluenza virus, respiratory syncytial virus, rinderpest virus, Sendai virus, canine tracheobronchitis virus, turkey rhinotracheitis virus, etc.) | 65 |
20080206281 | Method For Producing Storage Stable Viruses and Immunogenic Compositions Thereof - The invention relates to methods for producing storage stable virus compositions. In certain embodiments, the invention relates to one or more formulations and process steps which result in storage stable virus compositions, wherein the composition is storage stable as a lyophilized solid composition or a frozen liquid composition. | 08-28-2008 |
20080220018 | VACCINE COMPOSITION FOR VACCINATING DOGS AGAINST CANINE INFECTIOUS RESPIRATORY DISEASE(CIRD) - A vaccine composition for vaccinating dogs comprising any one or more of (a) an agent capable of raising an immune response against | 09-11-2008 |
20080233150 | RESPIRATORY SYNCYTIAL VIRUS-VIRUS LIKE PARTICLE (VLPS) - The present invention discloses and claims virus like particles (VLPs) that express and/or contains RSV proteins. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing immunity to infections, including RSV. | 09-25-2008 |
20090136544 | Interfering RNAs Targeting the Morbillivirus Nucleoprotein Gene - The invention relates to interfering RNAs (siRNAs, shRNAs or pre-miRNAs) directed against conserved regions of the mRNA of the N gene encoding the morbillivirus nucleoprotein. The invention also relates to the use of said interfering RNAs for the production of medicaments for use in the treatment or prevention of a morbillivirus infection. | 05-28-2009 |
20090186050 | Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains - The invention relates to an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae with one or more genetic modifications. The present invention also relates to the mutant components, i.e., nucleic acids and proteins, of these mutant mammalian MPVs. These mutant mMPV can be attenuated. These mutant mMPVs can encode non-native sequences. The invention further relates to vaccine formulations comprising the mMPV, including recombinant and chimeric forms of said viruses. The vaccine preparations of the invention encompass multivalent vaccines, including bivalent and trivalent vaccine preparations. In addition, the invention relates to chimeric viral RNA polymerase complex and assays using these chimeric RNA polymerase complexes. The chimeric RNA polymerase complexes of the invention are composed of different RNA polymerase components from different viruses of the family of paramyxoviridae. | 07-23-2009 |
20090274727 | Recombinant RSV Virus Expression Systems And Vaccines - The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene. | 11-05-2009 |
20100068226 | Polynucleotides and Uses Thereof - The present invention provides an isolated polynucleotide comprising or consisting of the nucleotide sequence encoding the G protein of human respiratory syncytial virus (RSV), wherein the nucleotide sequence is codon optimised for expression in mammalian cells and wherein the polynucleotide provides increased expression of the G protein in mammalian cells relative to expression of the wildtype RSV-G gene. Preferably, the polynucleotide comprises or consists of the nucleotide sequence of SEQ ID NO:2. Further aspects of the invention provide pharmaceutical compositions, in particular vaccines, for use in methods of immunising a subject against RSV infection. | 03-18-2010 |
20100239611 | Combination adjuvant formulation - Methods and compositions for enhancing an immune response to a selected antigen are described. The methods are useful for the treatment and prevention of microbial infections, such as infections caused by bacteria, viruses, fungi and parasites. The methods and compositions include host defense peptides, polyphosphazenes and immunostimulatory sequences to enhance the immune response to a coadministered antigen. | 09-23-2010 |
20100278862 | Nipah Virus Vaccines - The present invention relates to recombinant anti-Nipah virus vaccines and the administration of such vaccines to animals, advantageously pigs. Advantageously, the anti-Nipah virus vaccine may comprise a recombinant avipox virus containing a Nipah virus glycoprotein gene. The invention encompasses methods of vaccinating animals, advantageously pigs, by administration of anti-Nipah virus vaccines that may comprise a recombinant avipox virus that may contain a Nipah virus glycoprotein gene. | 11-04-2010 |
20100291147 | RECOMBINANT RSV ANTIGENS - This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection. | 11-18-2010 |
20100316673 | NANOEMULSION VACCINES - The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides immunogenic nanoemulision compositions and methods of using the same to induce immune responses (e.g., immunity (e.g., protective immunity)) against a pathogenic virus of the paramyxoviridae family (e.g., a Paramyxovirinae virus (e.g., | 12-16-2010 |
20100330120 | HUMAN PARAINFLUENZA VIRUSES HAVING SEPARATED P AND C GENES - The invention provides self replicating infectious recombinant paramyxoviruses where the P and C genes are separated rated. The recombinant paramyxoviruses preferably have one or more attenuating mutations and/or at least one temperature sensitive mutation and one non-temperature sensitive mutation. In some embodiments, the recombinant paramyxovirus has a separate variant polynucleotide encoding a C protein and a separate monocistronic polynucleotide encoding a P protein. Also provided are compositions and methods for using the recombinant paramyxoviruses as described herein. | 12-30-2010 |
20110045023 | Recombinant RSV Virus Expression Systems And Vaccines - The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene. | 02-24-2011 |
20110189232 | RECOMBINANT HUMAN PARAINFLUENZA TYPE 1 VIRUSES (HPIV1s) CONTAINING MUTATIONS IN OR DELETION OF THE C PROTEIN ARE ATTENUATED IN AFRICAN GREEN MONKEYS AND IN CILIATED HUMAN AIRWAY EPITHELIAL CELLS AND ARE POTENTIAL VACCINE CANDIDATES FOR HPIV1 - Two recently characterized live attenuated HPIV1 vaccine candidates, rHPIV1-C | 08-04-2011 |
20110212130 | LIVE, ATTENUATED RESPIRATORY SYNCYTIAL VIRUS - The present invention features live, attenuated respiratory syncytial viruses (RSV) useful as vaccines against RSV infection and/or the development of severe RSV-associated illnesses. The disclosed viruses are attenuated to the extent of being nonpathogenic when administered to a subject but substantially retain the antigenic and immunogenic properties of wild-type RSV. | 09-01-2011 |
20110262483 | METHODS FOR ISOLATING ENVELOPED VIRUS-BASED VLPS FREE OF INFECTIOUS AGENTS - Enveloped virus-based virus-like particles (VLPs) that are free of infectious agents and substantially as immunogenic as corresponding VLPs prior to inactivation of infectious agents are described. Improved methods of inactivation infectious agents in preparations of enveloped virus-based VLPs are also described wherein the methods do not adversely affect the immunogenicity of the VLPs. | 10-27-2011 |
20110300180 | PLANT-DERIVED VACCINES AGAINST RESPIRATORY SYNCYTIAL VIRUS - A plant-derived vaccine against respiratory syncytial virus (RSV) is disclosed. The vaccine includes an immunogenic complex that includes plant cells transformed with a chimeric gene containing a nucleotide sequence adapted for protein expression in plants and an RSV coding sequence that encodes an antigenic protein of RSV. Also disclosed are methods of making the plant-derived vaccine of the invention, as well as transgenic plants, transgenic plant cells, and nucleic acid constructs useful in immunizing a mammal against RSV. | 12-08-2011 |
20110305727 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME - The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F. | 12-15-2011 |
20110311587 | Fusogenic virus-like particles and uses thereof - Provided herein are novel Paramyxovirus virus-like particles, wherein said virus-like particles are composed of surface glycoprotein G; surface glycoprotein F; and matrix protein M. Further provided is a vaccine comprising the virus-like particles described herein and a pharmaceutically acceptable carrier. Also provided is a method of vaccinating a subject against paramyxovirus infection comprising administering the vaccine described herein. | 12-22-2011 |
20120164176 | RSV F PROTEIN COMPOSITIONS AMD METHODS FOR MAKING SAME - The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F. | 06-28-2012 |
20120219588 | METHODS FOR PURIFICATION OF VIRUSES - The present invention provides methods for the purification of cell-associated viruses from adherent cells (e.g., MDCK or Vero cells). In particular, the present invention provides purification methods for the production of immunogenic compositions comprising a live attenuated cell-associated virus (e.g., an attenuated respiratory syncytial virus (RSV) or cold-adapted, and/or temperature sensitive influenza virus) that result in levels of host cell DNA (HCD), host cell protein (HCP) and non-specific endonuclease (e.g., Benzonase), which are below the specifications required by regulatory agencies. The immunogenic compositions can be used to actively immunize subjects or to generate antibodies for a variety of uses, including passive immunization and diagnostic immunoassays. | 08-30-2012 |
20120237546 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS - The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine. | 09-20-2012 |
20120288522 | Novel Pneumovirus Compositions and Methods For Using the Same - Provided are newly identified | 11-15-2012 |
20120308602 | Recombinant RSV Virus Expression Systems And Vaccines - The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene. | 12-06-2012 |
20130302371 | Immunogenic Respiratory Syncytial Virus Glycoprotein-Containing VLPs and Related Compositions, Constructs, and Therapeutic Methods - The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of Respiratory Syncytial Virus (RSV) infections and related disorders, including bronchiolitis and viral pneumonia. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against RSV. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against RSV infection, confer immunity against RSV infection, protect against RSV infection, and reduce the likelihood of infection by RSV infection. | 11-14-2013 |
20140044751 | RSV IMMUNIZATION REGIMEN - The invention relates to an immunization regimen whereby an infant is protected against respiratory syncytial virus (RSV) through administration of a first anti-RSV immune response inducing composition to his or her mother during pregnancy, followed by administration of a second anti-RSV immune response inducing composition to the infant after birth. | 02-13-2014 |
20140056941 | ANTIGENIC FORMULATION - The present invention pertains to an antigenic formulation comprising a biological antigen, wherein the formulation comprises an oil containing as a principle constituent a fatty acid ester of eleostearic acid. The invention also pertains to the use of the said oil to manufacture an antigenic formulation. | 02-27-2014 |
20140186397 | MODIFIED SENDAI VIRUS VACCINE AND IMAGING VECTOR - The present invention relates to a Sendai virus or recombinant Sendai virus vector. In particular the present invention provides methods, vectors, formulations, compositions, and kits for a modified Enders strain Sendai viral vector. An immunogenic vector can be used in any in vitro or in vivo system. Moreover, some embodiments include vectors for imaging virus growth, location and transmission. | 07-03-2014 |
20140248313 | COMBINATION ADJUVANT FORMULATION - Methods and compositions for enhancing an immune response to a selected antigen are described. The methods are useful for the treatment and prevention of microbial infections, such as infections caused by bacteria, viruses, fungi and parasites. The methods and compositions include host defense peptides, polyphosphazenes and immunostimulatory sequences to enhance the immune response to a coadministered antigen. | 09-04-2014 |
20140248314 | PRE-FUSION RSV F ANTIGENS - The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F. | 09-04-2014 |
20140271710 | LIQUID STABLE BOVINE VIRUS VACCINES - The present invention discloses liquid stable bovine vaccines that comprise a live attenuated virus, in sucrose, arginine, and methionine. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines. | 09-18-2014 |
20140271711 | ADENOVIRAL VECTOR-BASED RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE - The invention provides an adenovirus or adenoviral vector characterized by comprising a nucleic acid sequence encoding one or more Respiratory Syncytial Virus (RSV) antigens and one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein, as well as a method of inducing an immune response against RSV in a mammal by administering the adenovirus or adenoviral vector to the mammal. | 09-18-2014 |
20140341950 | RECOMBINANT AVIAN PARAMYXOVIRUS VACCINE AND METHOD FOR MAKING AND USING THEREOF - The present invention encompasses engineered APMV compositions or vaccines. The vaccine or composition may be a recombinant APMV composition or vaccine. The present invention encompasses methods for modifying the genome of APMV to produce recombinant APMV; modified APMV prepared by such methods; DNA and protein sequences; and methods for infecting cells and host animals with such recombinant APMV. | 11-20-2014 |
20150017207 | Methods and Compositions for Activation of Innate Immune Responses Through RIG-I Like Receptor Signaling - Compositions and methods are provided that enable activation of innate immune responses through RIG-I like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (PAMPs) that comprise elements initially characterized in, and derived from, the hepatitis C virus genome. | 01-15-2015 |
20150297713 | RSV MUCOSAL VACCINE - A composition comprising the following composition: an AD vehicle including a synthetic peptide and a lipid, wherein the synthetic peptide includes the amino acid sequence KnLm (wherein n is 4 to 8 and m is 11 to 20), a carboxylvinyl polymer and an RSV antigen. The composition has an antibody producing ability which is further higher than that of a conventional mucosal vaccine, hence capable of exerting excellent anti-virus antigen-specific IgA antibody- and IgG antibody-inducing effect in the nasal wash and the serum, respectively, even with an extremely small quantity of an RSV antigen. | 10-22-2015 |
20150368622 | ATTENUATION OF HUMAN RESPIRATORY SYNCYTIAL VIRUS BY GENOME SCALE CODON-PAIR DEOPTIMIZATION - Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV. | 12-24-2015 |
20160022808 | Method for cancer immunotherapy and pharmaceutical compositions based on oncolytic non-pathogenic Sendai virus - The invention relates to the field of immunology and medicine, more specifically, oncology, and can be useful for the treatment of patients with carcinomas and sarcomas. A pharmaceutical composition is provided which contains biologically active oncolytic Sendai virus strain Moscow PTA-13024, and a method of treating patients with said malignancies is developed including administration of the said composition to a patient's body. The strain Sendai-Moscow PTA-13024 is characterized by high oncolytic activity and safety for humans. The exploitation of the invention allows an increase in efficacy of treatment due to direct elimination of malignant cells via virus action and induction of anti-tumor immunity by viruses. | 01-28-2016 |
20160250319 | THERMOSTABLE RESPIRATORY SYNCTIAL VIRUS (RSV) VACCINE COMPOSITIONS | 09-01-2016 |
424212100 | Measles virus or mumps virus | 12 |
20090074816 | TISSUE TARGETED ANTIGENIC ACTIVATION OF THE IMMUNE RESPONSE TO CANCERS - The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The formulations of the invention thereby facilitate activation of a treatment response to a cancer in a particular tissue or organ. The compositions may for example include killed or attenuated microbial pathogens, and may be administered at sites distant from the cancer, for example the skin. In some embodiments, microbial species of endogenous flora that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions. In alternative embodiments, exogenous microbial pathogens that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions. The administration of the immunogenic compositions may be repeated relatively frequently over a relatively long period of time. In embodiments for intradermal or subcutaneous injection, dosages may be adjusted so that injections reproduce a consistent visible delayed inflammatory immune reaction at the successive site or sites of administration. | 03-19-2009 |
20100040650 | Virus-Like paramyxovirus particles and vaccines - The present invention is directed to alphavirus virus-like particles produced by synthesizing in cell, including in vivo, structural proteins in the absence of other alphavirus proteins. In particular, these virus-like particules vaccines induce cellular and humoral immune responses that can block or inhibit alphavirus infections. Also disclosed are methods of vaccinating subjects with virus-like particles and vectors encoding the same. | 02-18-2010 |
20110014231 | ANTI-MEASLES CANCER IMMUNOTHERAPY - The present invention provides methods for treating specific populations of cancer patients by immunotherapy. The methods comprise administering an immunogenic composition eliciting an immune response to measles virus to patients having measles virus-immunoreactive cancer cells. | 01-20-2011 |
20110150927 | Stabilisation of Viral Microparticles - A micro-particulate dry powder composition comprising a viral particle can be prepared by spray-drying a mixture of the viral particle and a stabilizing carbohydrate using an outlet temperature of no more than 60° C. | 06-23-2011 |
20110243988 | Methods and Compositions for Stabilization of a Virus Vaccine - This invention provides compositions and methods for stabilizing a live attenuated virus in dried formulations. In particular, compositions and methods of preparing a dried vaccine are provided that stabilize the viability of live vaccines such as measles and adenovirus at room temperature. | 10-06-2011 |
20120039935 | METHODS OF TREATING MEASLES INFECTIOUS DISEASE IN MAMMALS - The invention provides for a measles vaccine utilizing a human codon-optimized polynucleotide encoding a measles virus polypeptide, such as HA or F protein. Optionally, the vaccine is administered with an adjuvant and is especially useful for immunizing an infant mammal. | 02-16-2012 |
20130309268 | COMPOSITIONS INCLUDING TRANSFER FACTOR DERIVED FROM EGGS - A non-mammalian transfer factor, compositions including the non-mammalian transfer factor, and methods for generating and preparing the non-mammalian transfer factor. The non-mammalian transfer factor may have specificity for one or more antigens. A method of using the non-mammalian transfer factor includes administering either antigen-specific non-mammalian transfer factor or antigen non-specific non-mammalian transfer factor to mammals to treat or prevent pathogenic infections in the mammals. | 11-21-2013 |
20140010840 | RECOMBINANT MUMPS VIRUS VACCINE - The present invention provides the complete genomic sequence of the epidemic mumps virus (MuV) strain MuV | 01-09-2014 |
20140199344 | ANTI-MEASLES CANCER IMMUNOTHERAPY - The present invention provides methods for treating specific populations of cancer patients by immunotherapy. The methods comprise administering an immunogenic composition eliciting an immune response to measles virus to patients having measles virus-immunoreactive cancer cells. | 07-17-2014 |
20150359873 | USE OF A GENETICALLY MODIFIED INFECTIOUS MEASLES VIRUS WITH ENHANCED PRO-APOPTOTIC PROPERTIES (MV-DELTAC VIRUS) IN CANCER THERAPY - The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory C protein has been knocked out (MV-deltaC). It concerns in particular the use of said genetically modified infectious MV-deltaC in the treatment of malignant tumour or cancer conditions, and for the preparation of agents or compositions for such treatment. | 12-17-2015 |
20160081918 | NON-SPECIFIC DELAYED-TYPE HYPERSENSITIVITY RESPONSE TO TREAT HERPES SIMPLEX VIRUS INFECTION - A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection. | 03-24-2016 |
20160103130 | ANTI-MEASLES CANCER IMMUNOTHERAPY - The present invention provides methods for treating specific populations of cancer patients by immunotherapy. The methods comprise administering an immunogenic composition eliciting an immune response to measles virus to patients having measles virus-immunoreactive cancer cells. | 04-14-2016 |
424213100 | Canine distemper virus | 2 |
20100196420 | IMMUNOGENIC COMPOSITIONS, VACCINES AND DIAGNOSTICS BASED ON CANINE DISTEMPER VIRUSES CIRCULATING IN NORTH AMERICAN DOGS - Immunogenic compositions and broad-spectrum vaccines containing newly identified isolates of canine distemper virus (CDV) collected from a geographic area are provided. The newly identified isolates exhibit attributes of both European wildlife lineage CDV and one or both of Arctic and American-2 lineage CDV. Therefore, the vaccines are broadly protective against infection with European wildlife lineage CDV and either Arctic lineage CDV or American-2 lineage CDV, or both Arctic and American-2 lineage CDV. | 08-05-2010 |
20140056942 | LIQUID STABLE VIRUS VACCINES - The present invention discloses liquid stable vaccines that comprise a live attenuated virus, 10-30% sugar additive, and an amino acid. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines. | 02-27-2014 |
424214100 | Newcastle disease virus | 13 |
20090155310 | HN EPITOPE RECOGNIZED BY AVIAN IMMUNE SYSTEM AND ANTIGENIC VARIANT NEWCASTLE DISEASE VIRUSES CARRYING CHANGES IN THE EPITOPE - The present invention relates to an epitope of HN protein in Newcastle disease virus which can be recognized by an avian immune system and an antibody against the epitope, a method for detecting a Newcastle disease virus by using the antibody, and an antigenic variant of Newcastle disease virus carrying changes in the epitope. The epitope of HN protein and the antigenic variant of Newcastle disease virus can be used for developing efficient vaccines, and further, in diagnosing the Newcastle disease virus rapidly and exactly. | 06-18-2009 |
20090232845 | Newcastle disease virus monoclonal antibodies - Anti-peptide monoclonal antibodies (MAb's) specific for Exotic Newcastle Disease (END) are used for rapid diagnostic identification between poultry infected with vaccine strains of NDV (LaSota/B1) and END virus (ENDV). Exotic Newcastle Disease is a contagious and fatal viral disease of birds and poultry. The present invention provides for diagnostic detection of ENDV in commercial poultry. | 09-17-2009 |
20090258035 | AVIAN VIRUS VACCINES AND USES THEREOF - The present invention relates to poultry vaccines for prevention of Newcastle disease. | 10-15-2009 |
20090280144 | Recombinant newcastle disease virus RNA expression systems and vaccines - This invention relates to genetically engineered Newcastle disease viruses and viral vectors which express heterologous genes or mutated Newcastle disease viral genes or a combination of viral genes derived from different strains of Newcastle disease virus. The invention relates to the construction and use of recombinant negative strand NDV viral RNA templates which may be used with viral RNA-directed RNA polymerase to express heterologous gene products in appropriate host cells and/or to rescue the heterologous gene in virus particles. In a specific embodiment of the invention, the heterologous gene product is a peptide or protein derived from the genome of a human immunodeficiency virus. The RNA templates of the present invention may be prepared by transcription of appropriate DNA sequences using any DNA-directed RNA polymerase such as bacteriophage T7, T3, SP6 polymerase, or eukaryotic polymerase I. | 11-12-2009 |
20100247574 | CHIMERIC NEWCASTLE DISEASE VIRUS VLPs - The present invention discloses and claims chimeric virus like particles (VLPs) that express and/or contains Newcastle disease matrix protein. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising chimeric VLPs of the inventions. The invention also includes methods of making and administrating chimeric VLPs to vertebrates, including methods of inducing immunity to infections. | 09-30-2010 |
20120121644 | STICKY SOFT GEL FOR TREATING POULTRY - The present invention is directed to a composition, kit and method for delivering a soft flowable gel to a flock of poultry in barns, but can also be used in hatcheries or free range farms, for treating poultry with a therapeutic agent. The soft flowable gel comprises water, a gelling agent, a therapeutic agent and between about 0.05% and 0.15% xanthan gum. | 05-17-2012 |
20130315956 | NEWCASTLE DISEASE VIRUS AND THE USE THEREOF AS A VACCINE - The present invention relates to a new Newcastle disease viruses of any genotype and novel fragments of the Newcastle disease virus genome encoding for the F and HN proteins constructed by reverse genetics and recombination, highly antigenic, for preparing vaccines for the prevention of the Newcastle disease by reducing viral shedding or for using as vectors with other viruses, lyophilized or in oil emulsion. Likewise, it can be used as vector in combination with other pathogenic agents. | 11-28-2013 |
20140141043 | COMPOSITIONS, VECTORS, KITS, AND METHODS FOR IMMUNIZING AGAINST AVIAN INFECTIOUS BRONCHITIS VIRUS - Disclosed are compositions, vectors, kits, and methods for inducing an immune response against avian infectious bronchitis virus (IBV). In particular, the compositions, vectors, kits, and methods may be utilized to immunize poultry against disease associated with IBV infection or to protect poultry from IBV infection altogether. | 05-22-2014 |
20140170185 | EMULSION CONTAINING A NON-LIVE MEDICINAL SUBSTANCE - The present invention pertains to an emulsion comprising an aqueous phase and an oily phase, the aqueous phase containing a non-live medicinal substance, wherein the aqueous phase comprises at least 30% w/w sugar. The invention also pertains to a method to shield a medicinal substance present in an aqueous phase emulsified with an oily phase, from interaction with the oily phase, and to a vaccine comprising as an antigen a killed micro-organism or a subunit of a micro-organism, the antigen being present in an aqueous phase that is dispersed in an oily phase, wherein the aqueous phase comprises at least 30% w/w sugar. | 06-19-2014 |
20140199345 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES - The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease, to methods for the detection of such oligodeoxynucleotides and to cells to be used in these methods. | 07-17-2014 |
20140205633 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES - The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease, to methods for the detection of such oligodeoxynucleotides and to cells to be used in these method. | 07-24-2014 |
20150086590 | LPS VACCINE - A vaccine composition for birds comprising as an active ingredient a structure containing O-antigen derived from Gram-negative bacteria, provided that said structure does not contain a whole cell, and a process for preparing the same are provided. By using a structure containing O-antigen (e.g. lipopolysaccharide) derived from Gram-negative bacteria as an active ingredient in accordance with the present invention, alleviation of inoculation reaction and reduction in an amount of injection are attained as compared to the conventional whole-cells vaccine to thereby allow for the increase in the number of other antigens to be mixed therewith. | 03-26-2015 |
20160030550 | COMPOSITIONS, VECTORS, KITS, AND METHODS FOR IMMUNIZING AGAINST AVIAN INFECTIOUS BRONCHITIS VIRUS - Disclosed are compositions, vectors, kits, and methods for inducing an immune response against avian infectious bronchitis virus (IBV). In particular, the compositions, vectors, kits, and methods may be utilized to immunize poultry against disease associated with IBV infection or to protect poultry from IBV infection altogether. | 02-04-2016 |